Compare Neurocrine Biosciences Inc (NBIX) vs Quantumscape Corp (QS) Price & Performance

Neurocrine Biosciences IncTrade

Quantumscape CorpTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Quantumscape Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Quantumscape Corp trades at $6.07 (market cap $3.62B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.8× Quantumscape Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.

	NBIX	QS
Market Cap	$17.40B	$3.62B
Sector	Health	Consumer Cyclical
52-Week High	$180.55	$18.44
52-Week Low	$123.10	$5.86
Enterprise Value	$16.49B	$2.79B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 6 hours agoBullish View details →

QuantumScape rated buy as Eagle Line pilot shows fast, scalable battery production and strong commercialization potential.Seeking Alpha · 4 days agoBullish View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Quantumscape Corp

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.